Tata MF: Govt incentives will help Indian pharma cos reduce API imports from China: Tata Mutual Fund


Source: indiatimes.com indiatimes.com

Key Topics in this News Article:

News Snapshot:

The US generic market is a deflationary market and it de-grows every year, says Meeta Shetty , assistant fund manager. I want to talk to you first about this entire Atmanirbhar move that we have been seeing. API and the raw material for pharmaceuticals is largely bought from China. China is one of the biggest suppliers of API to India. Do you think our own Indian companies have the capacity and capability to be able to cater to the entire Indian API demand and replace imports completely? Yes, the API import is around $3.5 billion on a yearly basis and...